PT-141 (Bremelanotide) | 10mg

What is PT 141 (Bremelanotide)?

PT-141, also known as Bremelanotide, is a synthetic peptide analog of the melanocyte-stimulating hormone (α-MSH). It functions as a selective agonist of melanocortin receptors, primarily targeting the MC1 and MC4 receptors. This peptide is of significant interest in laboratory research due to its unique mechanism of action and potential applications in studying sexual dysfunction, neurological pathways, and receptor signaling.

Unlike traditional peptides that target single pathways, PT-141 interacts with multiple melanocortin receptors, offering a broader scope for research into central nervous system (CNS) regulation and receptor dynamics. It is administered via subcutaneous injection and has a rapid onset of action, making it a valuable tool for time-sensitive experimental studies.

Bremelanotide is currently being investigated for its role in modulating neural pathways related to sexual arousal and inflammatory responses. Its ability to activate melanocortin receptors makes it a promising candidate for further research in these areas.

How does PT 141 work?

PT-141 Peptide exerts its effects through activation of melanocortin receptors, particularly the MC4 receptor, which is widely expressed in the brain and plays a key role in regulating various physiological processes. Here’s a breakdown of its mechanism of action:

1. MC1 Receptor Activation: Bremelanotide has minimal affinity for MC1 receptors, which are primarily involved in pigmentation. This interaction is an area of interest in studies related to skin biology and immune modulation.
2. MC4 Receptor Activation: The primary focus of PT-141 research is its interaction with MC4 receptors. Activation of these receptors influences neural pathways associated with sexual arousal and energy homeostasis.
3. Dopaminergic Pathways: PT141 has been shown to stimulate the release of dopamine in certain brain regions, making it a valuable tool for studying reward mechanisms and behavioral responses.

Research on Peptide PT 141

Bremelanotide has been the subject of numerous preclinical and clinical studies, highlighting its potential applications in laboratory research. Key areas of investigation include:

• Sexual Dysfunction Research: Studies show that PT-141’s ability to activate melanocortin-4 (MC4) receptors plays a crucial role in neural pathways linked to sexual arousal and desire. Research has explored its potential in addressing erectile dysfunction (ED) and hypoactive sexual desire disorder (HSDD).
• Neurological & Behavioral Studies: Due to its effects on the central melanocortin system, Bremelanotide has been investigated for its influence on reward mechanisms, motivation, and behavioral responses, particularly in relation to sexual behavior and dopamine regulation.
• Cardiovascular Effects: Research has explored PT-141’s impact on blood pressure regulation and vascular function, as melanocortin receptors are involved in cardiovascular homeostasis. Some studies suggest it may cause transient increases in blood pressure.
• Metabolic Research: While Bremelanotide primarily affects sexual function, the broader melanocortin system also plays a role in energy balance. Some research suggests that melanocortin agonists could influence metabolic activity, but PT-141 itself is not a primary candidate for obesity or appetite regulation studies.
• Pain Modulation: Certain melanocortin receptor pathways are involved in pain perception. Preliminary studies suggest that Bremelanotide and related compounds could have potential applications in pain management, but more research is needed in this area.

These findings underscore the potential of PT-141 as a research tool for studying a wide range of physiological and neurological processes.

PT-141 Dosage Considerations in Research

Research studies have explored various PT-141 dosage parameters depending on experimental objectives and biological response factors. Studies indicate that factors such as receptor sensitivity, metabolic rate, and administration frequency influence research outcomes. Ongoing investigations continue to refine dosage for PT-141 in applications related to sexual function, neural pathways, and behavioral studies.

PT-141 Nasal Spray – Research and Potential Applications

While PT-141 is traditionally studied in injectable form, research into PT-141 nasal spray has gained interest due to its alternative delivery method. Studies are examining the absorption efficiency, bioavailability, and receptor activation potential of intranasal PT-141 administration.

While PT-141 injections remain the primary focus in research applications, nasal spray formulations are being investigated for their potential convenience and effectiveness in neuroendocrine studies and receptor activation research.

How Long Does PT-141 Last?

Studies examining how long PT-141 lasts suggest that its effects may vary depending on dosage, administration method, and individual metabolic factors. Research findings indicate that:

• Onset of Action: Effects are typically observed within 30 to 60 minutes post-administration.
• Duration: The biological effects of PT-141 may last between 6 to 12 hours, with variability based on receptor sensitivity and metabolic clearance.
• Half-Life: Research suggests that PT-141 has a half-life of approximately 4 to 6 hours, contributing to its rapid onset and sustained action in experimental models.

PT-141 for Men vs. PT-141 for Women

Research studies have examined PT-141 (Bremelanotide) for men and PT-141 for women, highlighting differences in response due to hormonal and neuroendocrine variations. Findings suggest that:

• In Men: PT-141’s activation of MC4R has been associated with enhanced erectile response and libido modulation.
• In Women: Studies indicate that PT-141 may contribute to increased sexual desire and improved arousal mechanisms.

PT-141 (Bremelanotide) – Structural and Molecular Properties

PT-141 (Bremelanotide) is a cyclic heptapeptide, derived from the alpha-melanocyte-stimulating hormone (α-MSH). It belongs to the class of melanocortin receptor agonists, specifically targeting MC4R and MC1R receptors.

Structurally, the cyclic conformation of PT-141 increases its binding affinity and stability, allowing for enhanced interaction with central nervous system pathways involved in sexual arousal and behavioral responses. Unlike its predecessor Melanotan II, PT-141 does not strongly affect melanin production, making it a selective research target in neuroendocrine and receptor signaling studies.

Its synthetic cyclic structure ensures receptor-specific activation while reducing metabolic degradation.

History and Development of PT 141 Peptide

PT 141 was developed as part of ongoing research into melanocortin receptor agonists. Initially derived from α-MSH, it was designed to overcome the limitations of earlier peptides by targeting specific receptor subtypes with greater precision. Over the years, PT 141 has been extensively studied for its potential applications in neuroscience, endocrinology, and immunology.

Today, PT 141 is widely used in laboratory research to explore the role of melanocortin receptors in various physiological processes. Its development represents a significant advancement in peptide-based research tools.

Applications of PT 141 (Bremelanotide) in Laboratory Research

Bremelanotide offers a wide range of applications in scientific research, including:

1. Neuroscience: Investigating the role of melanocortin receptors in neural pathways related to sexual arousal.
2. Endocrinology: Studying the effects of melanocortin receptor activation on hormone regulation and metabolic processes.
3. Immunology: Exploring the role of MC1 receptors in inflammatory responses and immune modulation.
4. Behavioral Studies: Examining the impact of PT 141 on motivation, reward, and other behavioral responses.

These applications make PT 141 a valuable tool for advancing our understanding of melanocortin receptor biology and its implications for various fields of research.

Possible Side Effects of PT 141

Research on PT-141 side effects suggests that it is generally well tolerated, but some studies report mild to moderate reactions. Commonly observed effects include:

• Nausea: The most frequently reported side effect, usually mild and short-lived.
• Headache: Some users may experience headaches, particularly during the initial stages of use.
• Flushing: A temporary sensation of warmth or redness, especially in the face.
• Mild Increase in Blood Pressure: A slight, temporary rise in blood pressure may occur in some individuals.
• Local Injection Site Reactions: Mild redness, swelling, or irritation at the injection site, which typically resolves on its own.

These side effects are typically temporary, but discontinuation may be necessary in case of severe reactions. However, if symptoms persist or become severe, consulting a healthcare professional is recommended.

PT 141 | Pre-Mixed Pen – Unit and Microgram (mcg), Milligram (mg) Analysis

PT141 (10mg)

A 10 mg PT-141 pen contains 200 units, with each unit equivalent to 50 micrograms. Unit Conversion for Research Purposes:

• 1 unit = 50mcg
• 5 units = 250mcg
• 10 units = 500mcg
• 12 units = 600mcg
• 15 units = 750mcg

These parameters allow for precise dosing and flexibility in research applications.